albuterol has been researched along with Alkalosis, Respiratory in 2 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Alkalosis, Respiratory: A state due to excess loss of carbon dioxide from the body. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We present a 19-month-old boy with a history of asthma who presented to the pediatric emergency department with noisy breathing and tachypnea partially responsive to albuterol." | 3.76 | A 19-month-old boy with recurrent respiratory distress. ( Cross, KP; Herr, SM; Randell, KA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cancado, JE | 1 |
| Mendes, ES | 1 |
| Arana, J | 1 |
| Horvath, G | 1 |
| Monzon, ME | 1 |
| Salathe, M | 1 |
| Wanner, A | 1 |
| Cross, KP | 1 |
| Randell, KA | 1 |
| Herr, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Evidence of pH Dependent ß2 Adrenergic Transport Mechanisms in the Airway[NCT01216748] | 10 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Effect of airway pH on albuterol responsiveness as reflected by the change in airway blood flow after 180μg albuterol by inhalation (ΔQaw) vs baseline. (NCT01216748)
Timeframe: 15 minutes after albuterol inhalation
| Intervention | changes from baseline in μl.min-1.ml-1 (Mean) | |||
|---|---|---|---|---|
| quiet breathing | eucapnic hyperventilation | hypocapnic hyperventilation | hypercapnic hyperventilation | |
| Health Controls | 16.8 | 14.5 | -0.2 | 2.0 |
"EBC samples were collected at each respiratory maneuver by directing the subject's exhaled breath into a pre-cooled (-10C) tube for 10 min.~pH was measured immediately after collection." (NCT01216748)
Timeframe: 10 minutes after each respiratory manouver.
| Intervention | pH (Mean) | |||
|---|---|---|---|---|
| quiet breathing | hypocapnic hyperventilation | hypercapnic hyperventilation | eucapnic hyperventilation | |
| Health Controls | 6.39 | 6.31 | 6.59 | 5.88 |
1 trial available for albuterol and Alkalosis, Respiratory
| Article | Year |
|---|---|
Effect of airway acidosis and alkalosis on airway vascular smooth muscle responsiveness to albuterol.
Topics: Acidosis, Respiratory; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albut | 2015 |
1 other study available for albuterol and Alkalosis, Respiratory
| Article | Year |
|---|---|
A 19-month-old boy with recurrent respiratory distress.
Topics: Acid-Base Equilibrium; Albuterol; Alkalosis, Respiratory; Aspirin; Asthma; Bicarbonates; Bites, Huma | 2010 |